Caroline Marschner

Caroline Marschner

Auto-generated profile, based on publicly available information

Caroline Marschner

Faculty of Science, Sydney School of Veterinary Science, The University of Sydney, Camperdown, Australia

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 March 2019 in Medical Mycology
Verified
Journal Article
Closed access
MKMark B Krockenberger
Mark B Krockenberger
CMCaroline Marschner
Caroline Marschner
PMPatricia Martin
Patricia Martin
GRGeorge Reppas
George Reppas
CHCatriona Halliday
Catriona Halliday
RMRichard Malik
Richard Malik
Although the point-of-care cryptococcal antigen lateral flow assay (LFA) has revolutionized the diagnosis of cryptococcosis in human patients, to date there has been no large-scale examination of this test in animals. We therefore assessed the LFA in cats, dogs and koalas suspected of having cryptococcosis. In sum, 528 serum specimens (129 from cats, 108 from dogs, 291 from koalas) were tested using the LFA and one of two commercially available latex cryptococcal antigen agglutination test (LCAT) kits. The LCAT is a proven and well-accepted method in veterinary patients and therefore taken as the “gold standard” against which the LFA was compared. The LFA achieved a sensitivity of 92%, 100%, and 98% in cats, dogs, and koalas, respectively, with corresponding negative predictive values of 94%, 100%, and 98%. The specificity of the LFA was 81%, 84%, and 62% for cats, dogs, and koalas, respectively, with corresponding positive predictive values of 76%, 48%, and 69%. These findings suggest the most appropriate role for the LFA is as a screening test to rule out a diagnosis of cryptococcosis in cats, dogs, and koalas. Point-of-care accessibility makes it equally suited for use in the field and as a cage-side test in veterinary hospitals. The suboptimal specificity of the LFA makes it less suited to definitive confirmation of cryptococcosis in animals; therefore, all LFA-positive test results should be confirmed by LCAT testing. The discrepancy between these observations and the high specificity of the LFA in humans may reflect differences in the host-pathogen interactions amongst the species.

27 April 2014 in Australian Veterinary Journal
Verified
Journal Article
Closed access
PDF file
CMC Marschner
C Marschner
CFC Flanagan
C Flanagan
DHDp Higgins
Dp Higgins
MKMark Krockenberger
Mark Krockenberger

17 August 2019 in Journal of Chemical Ecology
Verified
Journal Article
Closed access
PDF file
CMCaroline Marschner
Caroline Marschner
MKMark B. Krockenberger
Mark B. Krockenberger
DHDamien Higgins
Damien Higgins
CMChristopher Mitchell
Christopher Mitchell
BMBen Moore
Ben Moore

12 November 2019 in Scientific Reports
Verified
Journal Article
Open access
CMCaroline Marschner
Caroline Marschner
MKMark Krockenberger
Mark Krockenberger
DHDamien Higgins
Damien Higgins
Protective immunity is crucial for survival of any species, though the koala as a specialist feeder adapted to an exclusive diet of eucalypts that contain plant secondary metabolites of varying toxicity and of immunomodulatory property. Being constantly exposed to such dietary chemicals it raises the question of their immune effects in a specialist eucalypt feeder. This study demonstrates that natural levels of circulating eucalypt plant secondary metabolites have dose dependent in vitro effects on cytokine expression of koala peripheral blood mononuclear cells, suggesting a potential trade-off of reduced function in multiple arms of the immune system associated with koala’s use of its specialized dietary niche.

15 July 2017 in Bulletin of Environmental Contamination and Toxicology
Verified
Journal Article
Closed access
PDF file
CMCaroline Marschner
Caroline Marschner
DHDamien Higgins
Damien Higgins
MKMark Krockenberger
Mark Krockenberger

17 April 2024 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MGMerran Govendir
Merran Govendir
LVLarry Vogelnest
Larry Vogelnest
ASAmanda J Shapiro
Amanda J Shapiro
CMCaroline Marschner
Caroline Marschner
BKBenjamin Kimble
Benjamin Kimble
The pharmacokinetic profile of paracetamol in koalas is described when administered orally at 15 mg/kg; followed by the same dose, administered every 12 hours (hrs), repeated five times. After the initial oral administration, the median (range) maximal plasma concentration (Cmax), the time Cmax was reached (Tmax) and elimination half-life (t1/2) were 16.93 μg/mL (13.66 to 20.25 μg/mL); 4 hrs (4 to 8 hrs) and 5.54 hrs (4.66 to 7.67 hrs), respectively. When paracetamol was administered orally at 15 mg/mL every 12 hrs, the trough total plasma concentration range remained comparable to the therapeutic range in humans i.e. 4 to 20 μg/mL that is known to provide some analgesia. However, there is a smaller proportion of free drug (i.e. not bound to plasma proteins; and the active form) available in koala plasma (approximately 40% unbound) compared to human plasma (approximately 80% unbound). Consequently, even when there are similar total drug plasma concentrations in both koala and human plasma, the therapeutic efficacy may be reduced in koalas compared to humans. The initial oral dose and subsequent twice daily doses resulted in no obvious adverse effects in any koala. Haematology, plasma electrolyte and biochemical analyte values remained within their reference ranges eight hrs after the last dose but there was a significant change in alanine transaminase (ALT) levels (an increase), and in total protein (a decrease) (both p = 0.03). A dose of 15 mg/kg was also administered as a subcutaneous injection, diluted 50:50 with saline, to two koalas. As the oral formulation and the subcutaneous administration resulted in comparable absorption, the study focused on the oral profile. Based on these results there is an argument to recommend a slight increase in the oral paracetamol dose for the koala, however further investigation is required to confirm whether repeated administration of a slightly higher dose may be associated with more severe or additional significant changes in haematology, electrolytes or biochemical analytes. However, a preferable recommendation would be to administer this dosage of paracetamol in combination with another analgesic such as tramadol, as a subcutaneous injection, to improve efficacy.